AR072525A1 - Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo. - Google Patents

Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo.

Info

Publication number
AR072525A1
AR072525A1 ARP090102742A ARP090102742A AR072525A1 AR 072525 A1 AR072525 A1 AR 072525A1 AR P090102742 A ARP090102742 A AR P090102742A AR P090102742 A ARP090102742 A AR P090102742A AR 072525 A1 AR072525 A1 AR 072525A1
Authority
AR
Argentina
Prior art keywords
treatment
rheumatoid arthritis
mammals
beta defensins
beta defensin
Prior art date
Application number
ARP090102742A
Other languages
English (en)
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of AR072525A1 publication Critical patent/AR072525A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Reivindicacion 1: EI uso de una beta defensina de mamífero en la elaboracion de un medicamento para el tratamiento de la artritis reumatoidea. Reivindicacion 7: El uso de acuerdo con cualquiera de las reivindicaciones 1-6, en el cual la beta defensina de mamífero tiene por lo menos 80% de identidad con la secuencia de aminoácidos de SEC ID N°: 2. Reivindicacion 8: El uso de acuerdo con cualquiera de las reivindicaciones 1-7, en el cual la beta defensina de mamífero es la beta defensina humana 2.
ARP090102742A 2008-07-18 2009-07-17 Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo. AR072525A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP09160448 2009-05-15

Publications (1)

Publication Number Publication Date
AR072525A1 true AR072525A1 (es) 2010-09-01

Family

ID=41530821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102742A AR072525A1 (es) 2008-07-18 2009-07-17 Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo.

Country Status (17)

Country Link
US (2) US8232248B2 (es)
EP (1) EP2320928B1 (es)
JP (1) JP2011528334A (es)
KR (1) KR20110031970A (es)
CN (1) CN102159234A (es)
AP (1) AP2011005536A0 (es)
AR (1) AR072525A1 (es)
AU (1) AU2009272683A1 (es)
BR (1) BRPI0915778A2 (es)
CA (1) CA2730666A1 (es)
EA (1) EA201170220A1 (es)
IL (1) IL210716A0 (es)
MX (1) MX2011000567A (es)
NZ (1) NZ590469A (es)
TW (1) TW201004639A (es)
WO (1) WO2010007168A2 (es)
ZA (1) ZA201100460B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170218A1 (ru) * 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение воспалительных заболеваний бета-дефенсинами млекопитающих
NZ593653A (en) 2008-07-18 2012-09-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
KR101249702B1 (ko) * 2010-06-16 2013-04-05 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
ES2712098T3 (es) 2011-04-15 2019-05-09 Marine Polymer Tech Inc Tratamiento de infecciones por VHS con nanofibras de poli-N-acetilglucosamina
ES2637286T3 (es) 2011-07-08 2017-10-11 Defensin Therapeutics Aps Tratamiento oral de la enfermedad inflamatoria intestinal
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
KR102631542B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR20050089827A (ko) * 2002-12-19 2005-09-08 이츠차크 힐만 항균성 펩티드 억제물을 통한 질환 치료
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
WO2009043507A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EA201170218A1 (ru) 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение воспалительных заболеваний бета-дефенсинами млекопитающих
NZ593653A (en) 2008-07-18 2012-09-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins

Also Published As

Publication number Publication date
ZA201100460B (en) 2012-09-26
JP2011528334A (ja) 2011-11-17
MX2011000567A (es) 2011-02-23
EP2320928B1 (en) 2012-11-07
BRPI0915778A2 (pt) 2019-09-24
KR20110031970A (ko) 2011-03-29
US20120309686A1 (en) 2012-12-06
CA2730666A1 (en) 2010-01-21
WO2010007168A2 (en) 2010-01-21
NZ590469A (en) 2012-08-31
US8232248B2 (en) 2012-07-31
TW201004639A (en) 2010-02-01
WO2010007168A3 (en) 2010-06-17
AP2011005536A0 (en) 2011-02-28
EP2320928A2 (en) 2011-05-18
CN102159234A (zh) 2011-08-17
AU2009272683A1 (en) 2010-01-21
IL210716A0 (en) 2011-03-31
US20100016231A1 (en) 2010-01-21
EA201170220A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
AR072525A1 (es) Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo.
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
AR072032A1 (es) Tratamiento de enfermedades inflamatorias del intestino con beta defensinas de mamiferos
ES2689512T3 (es) Receptores de células T que reconocen MAGE restringido por HLA-A1 o a HLA-Cw7
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
CU20140035A7 (es) Proteínas de función dual para tratar trastornos metabólicos
BR112012021329A2 (pt) anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo.
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
GT201300131A (es) Metodos de tratamiento de trastornos asociados con el fgf21
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
ES2572215T3 (es) Anticuerpo neutralizante contra el receptor de prolactina Mat3 y su uso terapéutico
BR112014002173A2 (pt) proteínas purificadas
ECSP15031046A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
PH12015502100A1 (en) Reducing the risk of autoimmune disease
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20110023A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
AR095661A1 (es) Método de activación de adiponectina mediante hidrolizado de caseína
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal